•Źū“ś–{—Õą¬@V—Ģˆę•ŹĒŒóŒQƒVƒŠ[ƒY NoD36
–ʉuĒŒóŒQi‘ę2”ŁjIII[‚»‚Ģ‘¼‚Ģ–ʉuŽ¾Š³‚šŠÜ‚߂ā[
˜@•¶ ‹{ā@M”V@@1
VIIDŒ“”­«–ʉu•s‘SĒŒóŒQ @
 1DŒ“”­«–ʉu•s‘SĒŒóŒQF‘˜_ –ģXŽRŒbĶ@@7
 2D•”‡–ʉu•s‘SĒ @
@ i1jT|B{dĒ•”‡–ʉu•s‘SĒiSCIDj @
@@ 1jƒĮcŒ‡‘¹ĒiX˜A½dĒ•”‡–ʉu•s‘SĒj ‰Ŗ–ģ@@—ƒ@ 16
@@ 2jJAK3Œ‡‘¹Ē ŽR‰ŗ@@Šī@ 20
@@ 3jIL-7RƒæŒ‡‘¹Ē ‹ąŒ“@O˜a@ 25
@@ 4jCD45Œ‡‘¹Ē “c’†@Œj•ć@ 29
@@ 5jCD3ƒĀŒ‡‘¹Ē “c’†@Œj•ć@ 33
@@ 6jCD3 epsilonŒ‡‘¹Ē “c’†@Œj•ć@ 36
@@ 7jCD3ƒÄŒ‡‘¹Ē ‰Ŗ–{@Œ\—S@ 39
@@ 8jCoronin-1AŒ‡‘¹Ē ‰Ŗ–{@Œ\—S@ 43
@ i2jT|B|dĒ•”‡–ʉu•s‘SĒiSCIDj @
@@ 1jDNA recombination defect @
@@@‡@DNA recombination defectG‘˜_ ’J“ą]ŗG@ 49
@@@‡ARAG1Œ‡‘¹Ē/RAG2Œ‡‘¹Ē ’J“ą]ŗG@ 57
@@@‡BDCLRE1CiArtemisjŒ‡‘¹Ē ’J“ą]ŗG@ 60
@@@‡CDNA-PKcsiPRKDCjŒ‡‘¹Ē ’J“ą]ŗG@ 62
@@@‡DCernunnosiXLFjŒ‡‘¹Ē ’J“ą]ŗG@ 64
@@@‡EDNA ligase IViLIG4jŒ‡‘¹Ē ’J“ą]ŗG@ 66
@@ 2j×–ŌˆŁŒ`¬ĒCAK2Œ‡‘¹Ē ģ“‡@@Šó@ 68
@@ 3jADAŒ‡‘¹Ē —L‰ź@@³@ 72
@ i3jSCID‚ę‚č‚ąŒyĒ‚Č•”‡–ʉu•s‘SĒ @
@@ 1jDOCK2Œ‡‘¹Ē ‰Ŗ–{@Œ\—S@ 76
@@ 2jCD40ƒŠƒKƒ“ƒhŒ‡‘¹Ē
@@@iimmunodeficiency with hyper IgM type 1 iHIGM1jj
ŠÖ’†‰Ą“ŽŽq@ 80
@@ 3jCD40Œ‡‘¹Ē
@@@iimmunodeficiency with hyper IgM type 3 iHIGM3jj
ŠÖ’†‰Ą“ŽŽq@ 83
@@ 4jICOSŒ‡‘¹Ē ‰Į“”@@ŠĀ@ 85
@@ 5jCD3ƒĮŒ‡‘¹Ē ‘åģ@“N•½@ 87
@@ 6ji‰Ę‘°«jCD8Œ‡‘¹Ē ¬–ģ@•q–¾@ 90
@@ 7jZAP-70Œ‡‘¹Ēiselective T-cell defectj ¬–ģ@•q–¾@ 93
@@ 8jMHC class IŒ‡‘¹Ē ¬–ģ@•q–¾@ 99
@@ 9jMHC class IIŒ‡‘¹Ē ¬–ģ@•q–¾@104
@@10jITKŒ‡‘¹Ē ŒF–Ų@Œb—¢@108
@@11jMAGT1Œ‡‘¹ĒCXMENĒŒóŒQ ŒF–Ų@Œb—¢@112
@@12jDOCK8Œ‡‘¹Ē ŒF–Ų@Œb—¢@115
@@13jRhoHŒ‡‘¹ĒiRHOHj ‰Ŗ‘ŗ@”üŒĪ@119
@@14jMST1iSTK4jŒ‡‘¹Ē ‰Ŗ‘ŗ@”üŒĪ@122
@@15jTCRƒæŒ‡‘¹Ē ‰Ŗ‘ŗ@”üŒĪ@125
@@16jLCKŒ‡‘¹Ē –ž¶@‹IŽq@129
@@17jMALT1Œ‡‘¹Ē –ž¶@‹IŽq@133
@@18jIL-21Œ‡‘¹Ē –ž¶@‹IŽq@137
@@19jIL-21Žó—e‘ĢŒ‡‘¹Ē –ž¶@‹IŽq@140
@@20jCARD11Œ‡‘¹Ē ŽR‰ŗ@@Šī@143
@@21jBCL10Œ‡‘¹Ē ŽR‰ŗ@@Šī@147
@@22jOX40Œ‡‘¹Ē ŽR‰ŗ@@Šī@151
@@23jIKBKBŒ‡‘¹Ē ŽR‰ŗ@@Šī@155
@@24jLipopolysaccharide-responsiveC
@@@@ beige-like anchor proteiniLRBAjŒ‡‘¹Ē
‘åģ@“N•½@158
@@25jCD27Œ‡‘¹Ē ¼–{@˜a–¾@161
@@26jNIKŒ‡‘¹Ē ¼–{@˜a–¾@164
@@27jCTPS1Œ‡‘¹Ē ‰Ŗ–{@Œ\—S@167
@@28jƒĄ2-microglobulinŒ‡‘¹Ē ‰Ŗ–{@Œ\—S@171
@@29jOmennĒŒóŒQ ‰Ŗ–{@Œ\—S@175
 3D–ʉu•s‘S‚š”ŗ‚¤“Į’„“I‚ȏĒŒóŒQ @
@ i1jCongenital thrombocytopenia @
@@ 1jWiskott-AldrichĒŒóŒQ łŒ“@—m“ń@179
@@ 2jWIPŒ‡‘¹Ē łŒ“@—m“ń@183
@ i2jDNAC•œįŠQi2D•”‡–ʉu•s‘SĒ‚É‹LŚ‚³‚ź‚½‚ą‚ĢˆČŠOj @
@@ 1j–Ń×ŒŒŠĒŠg’£«‰^“®Žø’² …’J@C‹I@187
@@ 2j–Ń×ŒŒŠĒŠg’£«‰^“®Žø’²Ē—lŽ¾Š³1Œ^ ‚–Ų@³–«@192
@@ 3jNijmegenõF‘Ģ•sˆĄ’čĒŒóŒQ ¼‰Y@L–ē@197
@@ 4jBloomiƒuƒ‹[ƒ€jĒŒóŒQ ‹ąŽq@‰p—Y@200
@@ 5j–ʉu•s‘S-“®Œ“‘Ģ•sˆĄ’萫-Šē–ŹŠļŒ`ĒŒóŒQ-1iICF1ĒŒóŒQj ‰Į“”@@ŠĀ@203
@@ 6j–ʉu•s‘S-“®Œ“‘Ģ•sˆĄ’萫-Šē–ŹŠļŒ`ĒŒóŒQ-2iICF2ĒŒóŒQj ‰Į“”@@ŠĀ@205
@@ 7jPMS2Œ‡‘¹Ē 萒†@—Im@207
@@ 8jRNF168Œ‡‘¹ĒiRIDDLEĒŒóŒQj ¬‘q@—F”ü@209
@@ 9jDNA ligase 1Œ‡‘¹Ē Ą”g@“—_@213
@@10jMCM4Œ‡‘¹ĒiOMIM#609981j ‘吼@G“T@216
@ i3jŠļŒ`‚š”ŗ‚¤‹¹‘BŒ‡‘¹Ē @
@@ 1jDiGeorgeĒŒóŒQ ¬—с@ēŒb@219
@@ 2jCHARGEĒŒóŒQ ¬—с@ēŒb@222
@@ 3jƒEƒBƒ“ƒOƒhƒwƒŠƒbƒNƒXŒ‡‘¹Ē ¬—с@ēŒb@226
@ i4j–ʉuœŒ`¬ˆŁķ @
@@ 1j“īœ–Ń”Æ’įŒ`¬Ē ¬–ģ@—T”V@228
@@ 2jSchimkeĒŒóŒQ ‰Ę“‡@@Œś@231
@ i5j‚IgEĒŒóŒQiHIESj @
@@ 1jAD-HIESiJob'sĒŒóŒQj •õŠŻ@Žs@235
@@ 2jComel-NethertonĒŒóŒQ •õŠŻ@Žs@238
@@ 3jPGM3Œ‡‘¹Ē •õŠŻ@Žs@240
@ i6jœ‘•s‘S‚Ęƒeƒƒƒ‰[ƒ[ˆŪŽ‹@”\•s‘S‚š”ŗ‚¤ę“V«Šp‰»ˆŁķĒiDKCj
@@ 1ję“V«Šp‰»ˆŁķĒ@ŠT˜_ ‘ŗ¼@Gé@242
@@ 2jDyskerinŒ‡‘¹Ē‚É‚ę‚éXL-DKC ¬“‡@‘å‰p@245
@@ 3jNHP2Œ‡‘¹Ē‚É‚ę‚éAR-DKC ‘ŗć@“TŠ°@248
@@ 4jNOP10ˆŁķ‚É‚ę‚éAR-DKC ’JŒū—ŒbŽq@250
@@ 5jRTEL1Œ‡‘¹Ē‚É‚ę‚éAR-DKC ¬“‡@‘å‰p@253
@@ 6jTERCŒ‡‘¹Ē‚É‚ę‚éAD-DKC ¼”ö@M”Ž@256
@@ 7jTERTŒ‡‘¹Ē‚É‚ę‚éAD-DKC ¼ģ@‰p—¢@260
@@ 8jTINF2•ĻˆŁ‚É‚ę‚éAD-DKC ŠÖ‰®@—RŽq@263
@@ 9jTPP1Œ‡‘¹Ē‚É‚ę‚éAD-DKC —é–Ų@‹ŖŒå@266
@ i7jƒrƒ^ƒ~ƒ“B12‚Ę—tŽ_‘ćŽÓ‚ĢŒ‡‘¹ @
@@ 1jƒgƒ‰ƒ“ƒXƒRƒoƒ‰ƒ~ƒ“ II iTCN2jŒ‡‘¹Ē [”ö@•qK@269
@@ 2jˆā“`«—tŽ_‹zŽū•s‘SĒiSLC46A1Œ‡‘¹Ēj @
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@   @@@ –ģģiē“cj“Ž’ĆŽq@272  
@@ 3jMTHFD1Œ‡‘¹Ē łˆä@‰p—Y@276
@ i8jORAI1Œ‡‘¹ĒiIMD9j ¬‘q@—F”ü@283
@ i9jSTIM1Œ‡‘¹ĒiIMD10j ¬‘q@—F”ü@286
@i10jSTAT5BŒ‡‘¹Ē ‹g“c@—T•ć@288
@i11j–ʉu•s‘S‚š”ŗ‚¤ŠĢĆ–¬•ĀĒ«Ž¾Š³ Ą”g@“—_@290
@i12jIKAROSŒ‡‘¹Ē ‹g“c@—T•ć@292
@i13jFILSĒŒóŒQ Ą”g@“—_@294
@i14j•”‡–ʉu•s‘SĒ‡•¹‘½”­’°•ĀĒĒ “c‘ŗ@M‰ī@296
@i15jViciĒŒóŒQ “c‘ŗ@M‰ī@299
@i16jPNPŒ‡‘¹Ē —L‰ź@@³@301
@i17j–ʉu•s‘S‚š”ŗ‚¤–³Š¾«ŠOćó—tŒ`¬ˆŁķĒiEDA-IDj @
@@@@NEMOˆŁķĒ‚ĘNFKBIAˆŁķĒ ‰Ķ‡@•üŽ÷@304
@i18jLUBACˆŁķĒiHOIL-1Œ‡‘¹Ē‚ĘHOIPŒ‡‘¹Ēj ‰Ķ‡@•üŽ÷@311
 4DR‘ĢŽY¶•s‘SĒ @
@ i1jB×–EŒ‡”@‚ ‚é‚¢‚Ķ’˜–¾‚Č’į‰ŗ‚š”ŗ‚¢C‚·‚ׂĂĢ
@@@ŒŒ“–ʉuƒOƒƒuƒŠƒ“‚ĢƒAƒCƒ\ƒ^ƒCƒv‚Ģ’˜–¾‚Č’į‰ŗ‚šŽ¦‚·‚ą‚Ģ
@
@@ 1jBTKŒ‡‘¹Ē ‹ąŒ“@O˜a@317
@@ 2jƒŹd½Œ‡‘¹ĒiAGM1j ‹ąŒ“@O˜a@321
@@ 3jƒÉ5Œ‡‘¹ĒiAGM2j ‹ąŒ“@O˜a@325
@@ 4jIgƒæŒ‡‘¹ĒiAGM3j ‹ąŒ“@O˜a@329
@@ 5jIgƒĄŒ‡‘¹Ē iAGM6j Æ–ģ@Œ°G@332
@@ 6jBLNKŒ‡‘¹Ē iAGM4j Æ–ģ@Œ°G@337
@@ 7jPI3ƒLƒi[ƒ[Œ‡‘¹Ē iAGM7j Æ–ģ@Œ°G@341
@@ 8jE47“]ŽŹˆöŽqŒ‡‘¹Ē ‰Ŗ–ģ@@—ƒ@345
@@ 9j’įƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒĒ‚š”ŗ‚¤œ‘ˆŁŒ`¬Ē ‰Ŗ–ģ@@—ƒ@349
@@10j–ʉu•s‘S‡•¹‹¹‘BŽī ‰Ŗ–ģ@@—ƒ@351
@ i2jB×–E”³ķ‚©’į‰ŗ‚š”ŗ‚¢C­‚Č‚­‚Ę‚ą2Žķ—Ž‚Ģ
@@@@ŒŒ“–ʉuƒOƒƒuƒŠƒ“‚ĢƒAƒCƒ\ƒ^ƒCƒv‚Ģ’˜–¾‚Č’į‰ŗ‚šŽ¦‚·‚ą‚Ģ
@
@@ 1j•Ŗ—Ž•s”\Œ^–ʉu•s‘SĒ X”ö@—FG@354
@@ 2jCD19Œ‡‘¹ĒiCVID3j ‹{–{@’qŽj@359
@@ 3jCD81Œ‡‘¹ĒiCVID6j ‹{–{@’qŽj@363
@@ 4jCD20Œ‡‘¹ĒiCVID5j ‹{–{@’qŽj@367
@@ 5jCD21Œ‡‘¹Ē ‘«ō@”ü•ä@372
@@ 6jTACIˆŁķĒ ‘«ō@”ü•ä@376
@@ 7jBAFF-RŒ‡‘¹Ē ‘«ō@”ü•ä@380
@@ 8jTWEAKŒ‡‘¹Ē ‹v•Ū“c^—@384
@@ 9jNF-ƒČB2Œ‡‘¹ĒiCVID10j ‹v•Ū“c^—@388
@@10jNLRP12Œ‡‘¹Ē ‹v•Ū“c^—@393
@@11jMOGSŒ‡‘¹Ē ¬–ģ^‘¾˜Y@397
@@12jTRNT1Œ‡‘¹Ē ¬–ģ^‘¾˜Y@400
@@13jTTC37Œ‡‘¹Ē ¬–ģ^‘¾˜Y@403
@ i3jIgM³ķ‚Ü‚½‚Ķ‚’l‚ĘB×–E”³ķ‚šŽ¦‚·CŒŒ“IgG‚ĘIgA‚Ģ’˜–¾‚Č’į‰ŗ‚šŽ¦‚·‚ą‚Ģ
@@ 1jAIDŒ‡‘¹Ē
@@@iimmunodeficiency with hyper IgM type 2 iHIGM2jj
ŠÖ’†‰Ą“ŽŽq@406
@@ 2jUNGŒ‡‘¹Ē
@@@iimmunodeficiency with hyper IgM type 5 iHIGM5jj
ŠÖ’†‰Ą“ŽŽq@408
@@ 3jINO80Œ‡‘¹Ē ‹g“c@—T•ć@410
@@ 4jMSH6Œ‡‘¹Ē “c‘ŗ@M‰ī@412
@ i4jB×–E”‚Ķ³ķ‚ŁCƒAƒCƒ\ƒ^ƒCƒv‚ ‚é‚¢‚ĶŒy½‚ĢŒ‡‘¹Ē @
@@ 1jActivated PI3K-delta syndromeiAPDSj ‘åģ@“N•½@414
@@ 2j–ʉuƒOƒƒuƒŠƒ“H½’čķ•”ˆā“`ŽqŒ‡ŽøĒ
@@@iIgd½ˆā“`Žq‚Ģ•ĻˆŁ‚Ü‚½‚ĶŒ‡Žøj
‹ąŽq@‰p—Y@418
@@ 3jƒČ½Œ‡‘¹Ē ätŒĖ@“¹“æ@422
@@ 4jŒĒ”­«IgGƒTƒuƒNƒ‰ƒXŒ‡‘¹Ē ‹ąŽq@‰p—Y@425
@@ 5jIgA‚ĘIgGƒTƒuƒNƒ‰ƒX‚ĢŒ‡‘¹Ē ‹Źˆä@—T–ē@428
@@ 6j‘I‘š“IIgAŒ‡‘¹Ē X“c@Gs@433
@@ 7jIgM’P“ĘŒ‡‘¹Ē X“c@Gs@436
@ i5j“ĮˆŁR‘ĢŒ‡‘¹Ē œA–Ų@@—y@438
@ i6j“ūŽ™ˆź‰ß«’įƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒĒ œA–Ų@@—y@441
@ i7ję“V«B×–EƒŠƒ“ƒp‹…‘‰ĮĒ œA–Ų@@—y@444
 5D–ʉu’²ßįŠQ @
@ i1j‰Ę‘°«ŒŒ‹…ęƐH«ƒŠƒ“ƒp‘gD‹…iFHLjĒŒóŒQ @
@@ 1jF‘f’EŽø‚š”ŗ‚ķ‚Č‚¢FHLĒŒóŒQ @
@@@‡@PerforinŒ‡‘¹ĒiFHL2j Žs‘ŗ@‘ģ–ē@448
@@@‡AUNC13D/Munc13-4Œ‡‘¹ĒiFHL3j Žs‘ŗ@‘ģ–ē@454
@@@‡BSyntaxin11Œ‡‘¹ĒiFHL4j Žs‘ŗ@‘ģ–ē@457
@@@‡CSTXBP2/Munc18-2Œ‡‘¹ĒiFHL5j Žs‘ŗ@‘ģ–ē@459
@@@‡DSH2D1AŒ‡‘¹Ē iXLP-1j ˜a“c@‘׎O@461
@@@‡EXIAPŒ‡‘¹Ē iXLP-2j ˜a“c@‘׎O@465
@@ 2jF‘f’EŽø‚š”ŗ‚¤FHLĒŒóŒQ @
@@@‡@Chédiak-Higashi ĒŒóŒQ Īˆä@žÄˆź@468
@@@‡AGriscelliĒŒóŒQ type 2 Īˆä@žÄˆź@472
@@@‡BHermansky-PudlakĒŒóŒQ type 2 Īˆä@žÄˆź@475
@@@‡CHermansky-PudlakĒŒóŒQ type 9 Īˆä@žÄˆź@479
@ i2jT regulatory cells genetic defects @
@@ 1j–ʉu’²®•s‘SC‘½”­«“ą•Ŗ”åįŠQC’°įŠQC
@@@@X˜A½iIPEXjĒŒóŒQ
¬—с@ˆź˜Y@481
@@ 2jCD25Œ‡‘¹Ē ¬—с@ˆź˜Y@485
@@ 3jCytotoxic T lymphocyte-associated antigen-4
@@@ iCTLA-4j•ĻˆŁ
¬—с@ˆź˜Y@488
@@ 4jSTAT3‹@”\Šl“¾Œ^•ĻˆŁ ¬—с@ˆź˜Y@492
@ i3jAutoimmunity with or without lymphoproliferation @
@@ 1jƒJƒ“ƒWƒ_Š“õ‚ĘŠOćó—tŒ`¬ˆŁķ‚š”ŗ‚¤
@@@@Ž©ŒČ–ʉu«‘½‘B«“ą•Ŗ”å•s‘SĒ
¬—с@ˆź˜Y@496
@@ 2jITCHŒ‡‘¹Ē ¬—с@ˆź˜Y@501
@@ 3jTripeptidyl-peptidase IIiTPP2jŒ‡‘¹Ē ¬—с@ˆź˜Y@505
@ i4jŽ©ŒČ–ʉu«ƒŠƒ“ƒp‘BĒŒóŒQiALPSj @
@@ 1jFASˆŁķ‚š”ŗ‚¤Ž©ŒČ–ʉu«ƒŠƒ“ƒp‘BĒŒóŒQ ‰““”@–¾Žj@509
@@ 2jFASLGˆŁķ‚š”ŗ‚¤Ž©ŒČ–ʉu«ƒŠƒ“ƒp‘BĒŒóŒQ ‰““”@–¾Žj@514
@@ 3jCaspase 10ˆŁķ‚š”ŗ‚¤Ž©ŒČ–ʉu«ƒŠƒ“ƒp‘BĒŒóŒQ ‰““”@–¾Žj@518
@@ 4jCaspase-8 iCASP8jŒ‡‘¹Ē
@@@iautoimmune lymphoproliferative syndrome type 2B:ALPS2B
¬—с@ē‰Ą@522
@@ 5jFADDŒ‡‘¹Ē ¬—с@ē‰Ą@526
@@ 6jPRKCƒĀŒ‡‘¹Ē iALPS3C CVID9j ¬—с@ē‰Ą@528
@ i5j‘å’°‰Š‚š”ŗ‚¤–ʉu’²ß•s‘S @
@@ 1jIL-10Œ‡‘¹Ē łŒ“@—m“ń@531
@@ 2jIL-10RƒæŒ‡‘¹Ē łŒ“@—m“ń@535
@@ 3jIL-10RƒĄŒ‡‘¹Ē łŒ“@—m“ń@538
@@ 4jNFAT5ƒnƒvƒ•s‘S łŒ“@—m“ń@541
@ i6jType1 interferonopathies @
@@ 1jAicardi-Goutières ĒŒóŒQ ˆ¢•”@ƒ–ē@544
@@ 2jSpondyloenchondrodysplasia with immune dysregulation
@@@iSPENCDIj
¼¬X—²‘¾@551
@@ 3jƒAƒfƒmƒVƒ“ƒfƒAƒ~ƒi[ƒ[iADAj2Œ‡‘¹Ē X”ö@—FG@554
 6Dę“V«H×–E‹@”\•s‘SĒ‹y‚ŃŒ‡‘¹Ē @
@ i1ję“V«D’†‹…Œø­Ē @
@@ 1ję“V«D’†‹…Œø­ĒFŠT˜_ ¬—с@³•v@558
@@ 2jElastase Œ‡‘¹ĒiSCN1j aŒū@—mŽq@562
@@ 3jGFI1 Œ‡‘¹ĒiSCN2j aŒū@—mŽq@567
@@ 4jKostmann•aiSCN3j Īģ@’؍P@570
@@ 5jG6PC3Œ‡‘¹Ē‚ĘDursunĒŒóŒQ “y‹@Šx•F@574
@@ 6jVPS45Œ‡‘¹ĒiSCN5j “‚ģ@C•½@579
@@ 7j“œŒ“•aIb Žšˆä@‹K•v@581
@@ 8jŽüŠś«D’†‹…Œø­Ē •½“c@@C@584
@@ 9jX˜A½«ę“V«D’†‹…Œø­Ē iSCNXj āV“”@‘Žu@589
@@10jp14/LAMTOR2Œ‡‘¹Ē “y‹@Šx•F@592
@@11jBarthĒŒóŒQ iMGCA2j ‘å’Ė@”ŽŽ÷@594
@@12jCohenĒŒóŒQ ‰Ŗ–{@L•F@597
@@13jClericuzioĒŒóŒQiD’†‹…Œø­Ē‚š”ŗ‚¤‘½Œ`”ē•†ˆŽkĒj “c’†@‹Å¶@600
@@14jJAGN1Œ‡‘¹ĒiSCN6j “‚ģ@C•½@605
@@15j3-ƒƒ`ƒ‹ƒOƒ‹ƒ^ƒRƒ“Ž_”AĒtypeVII iMGCA7j Ü‹@ŒšŽ”@608
@@16jG-CSFŽó—e‘ĢŒ‡‘¹Ē ¼‘ŗ@Žu”æ@613
@ i2jD’†‹…‰^“®”\‚ĢįŠQ @
@@ 1j”’ŒŒ‹…Ś’…•s‘SĒ1Œ^ ˜a“c@‘׎O@616
@@ 2j”’ŒŒ‹…Ś’…•s‘SĒ2 Œ^ ˜a“c@‘׎O@619
@@ 3j”’ŒŒ‹…Ś’…•s‘SĒ3Œ^ ˜a“c@‘׎O@621
@@ 4jRAC2Œ‡‘¹Ē •zˆä@”ŽK@623
@@ 5jƒĄ-CƒĮ-ActinˆŁķĒ •zˆä@”ŽK@627
@@ 6jNP«Ž•Žü‰Š –k‘ŗ@³”Ž@632
@@ 7jPapillon-LefévreĒŒóŒQ —Ž‡@–LŽq@636
@@ 8jD’†‹…“ńŽŸi“ĮŽźjč÷—±Œ‡‘¹Ē ˜a“c@‘׎O@641
@@ 9jShwachman-DiamondĒŒóŒQ “nē³Œ’ˆź˜Y@644
@ i3jH×–E‚ĢŠˆ«Ž_‘fŽY¶įŠQ @
@@@@–«“÷‰čŽīĒi–«“÷‰čŽīĒŠT˜_AX˜A½«–«“÷‰čŽīĒA
@@@@p22-phoxiCYBAjŒ‡‘¹ĒAp47-phoxiNCF1jŒ‡‘¹ĒA
@@@@p67-phoxiNCF2jŒ‡‘¹ĒAp40-phoxiNCF4jŒ‡‘¹Ēj
¼‘ŗ@–LŽ÷@648
@ i4j‚»‚Ģ‘¼‚ĢįŠQ @
@@ 1jIRF8Œ‡‘¹Ē 萒†@—Im@658
@@ 2jGATA2Œ‡‘¹Ē 萒†@—Im@660
@@ 3jCSF2Žó—e‘Ģ•ĻˆŁ‚É‚ę‚é”x–E’`”’Ē “cąV@—§”V@663
 7DŽ©‘R–ʉuˆŁķ @
@ i1jTIR“`’BŒo˜HŒ‡‘¹Ē @
@@ 1jIRAK4Œ‡‘¹Ē ‚“c@‰pr@667
@@ 2jMyD88Œ‡‘¹Ē ‚“c@‰pr@673
@ i2jWHIMiįnęŅC’įƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒĒCˆÕŠ“õ«C
@@@@ƒ~ƒGƒƒJƒeƒLƒVƒXjĒŒóŒQ
‹ąąV@L—Y@677
@ i3jįnęŅó•\”ē”­ˆēˆŁķĒ @
@@ 1jįnęŅó•\”ē”­ˆēˆŁķĒ Ī’n@®‹»@681
@ i4jdĒƒEƒCƒ‹ƒXŠ“õĒˆÕŠ“õŽ¾Š³
@@@iPredisposition to severe viral infectionj
@
@@ 1jSTAT1Œ‡‘¹ĒiOMIM#613796j ‘吼@G“T@687
@@ 2jSTAT2Œ‡‘¹ĒiOMIM not assignedj ‘吼@G“T@690
@@ 4jIRF7Œ‡‘¹ĒiOMIM#616345j ‘吼@G“T@693
@ i5j’Pƒƒwƒ‹ƒyƒX”]‰ŠˆÕŠ“õŽ¾Š³
@@@iHerpes simplex encephalitisjiHSEj
@
@@ 1jTLR3Œ‡‘¹ĒiOMIM#613002j ‘吼@G“T@695
@@ 2jUNC93B1Œ‡‘¹ĒiOMIM#610551j ‘吼@G“T@699
@@ 3jTRAF3Œ‡‘¹ĒiOMIM#614849j ‘吼@G“T@701
@@ 4jTRIFŒ‡‘¹ĒiOMIM#614850j ‘吼@G“T@703
@@ 5jTBK1Œ‡‘¹ĒiOMIM not assignedj ‘吼@G“T@706
@ i6j^‹ŪĒˆÕŠ“õŽ¾Š³iPredisposition to invasive fungal diseasesj @
@@ 1jCARD9Œ‡‘¹ĒiCANDF2j ‘ģ@½ˆź@709
@ i7j–«”ē•†”S–ŒƒJƒ“ƒWƒ_ĒˆÕŠ“õŽ¾Š³
@@@iChronic mucocutaneous candidiasisj
@
@@ 1jIL-17RAŒ‡‘¹ĒiCANDF5j@613953 ó–ģ@FŠī@714
@@ 2jIL-17FˆŁķĒiCANDF6j ģ@—ēŽq@719
@@ 3jSTAT1gain-of-function mutation iCANDF7j ‰Ŗ“c@@Œ«@723
@@ 4jACT1ˆŁķĒiCANDF8j ā“c@‰€Žq@728
@ i8jƒgƒŠƒpƒmƒ\[ƒ}•a ’†“ˆ@‹ŹŒb@731
@ i9jŒĒ—§«ę“V«–³äBĒ ¼Œ“@Nō@736
i10jƒƒ“ƒfƒ‹ˆā“`Œ^ƒ}ƒCƒRƒoƒNƒeƒŠƒAˆÕŠ“õŽ¾Š³
@@@iMendelian susceptibility to mycobacterial diseasej
@
@@ 1jIL-12Žó—e‘ĢƒĄ1½Œ‡‘¹Ē ‚“c@‰pr@741
@@ 2jIL-12p40Œ‡‘¹Ē ‚“c@‰pr@745
@@ 3jIFN-ƒĮŽó—e‘Ģ1Œ‡‘¹Ē ‚“c@‰pr@748
@@ 4jIFN-ƒĮŽó—e‘Ģ2Œ‡‘¹Ē ‚“c@‰pr@753
@@ 5jSTAT1Œ‡‘¹Ē ‚“c@‰pr@757
@@ 6jMacrophage gp91-phoxŒ‡‘¹Ē ‚“c@‰pr@761
@@ 7jIRF8Œ‡‘¹Ē ‚“c@‰pr@765
@@ 8jISG15Œ‡‘¹Ē ‚“c@‰pr@769
@@ 9jTYK2Œ‡‘¹Ē ¼–{@˜a–¾@771
 8DŽ©ŒČ‰ŠĒ«Ž¾Š³ @
@ i1jƒCƒ“ƒtƒ‰ƒ}ƒ\[ƒ€‚ɉe‹æ‚·‚éˆŁķ @
@@ 1j‰Ę‘°«’n’†ŠC”M‚Ģ—Տ° ‰E“c@“Žu@775
@@ 2jƒƒoƒƒ“Ž_ƒLƒi[ƒ[Œ‡‘¹Ēi‚IgDĒŒóŒQj “c’†@F”V@779
@@ 3jPLCG2ˆŁķĒ ˆäąV@˜aŽi@783
@ i2jƒCƒ“ƒtƒ‰ƒ}ƒ\[ƒ€‚ÉŠÖ˜A‚µ‚Č‚¢ó‘Ō @
@@ 1jTNFŽó—e‘ĢŠÖ˜AŽüŠś«ĒŒóŒQ ˆä“c@O–¾@787
@@ 2j‰»”^«–³‹Ū«ŠÖß‰ŠE‰óįs«”^”ēĒEƒAƒNƒliPAPAjĒŒóŒQ ‚“cŽŃ“Ž”ü@794
@@ 3jBlauĒŒóŒQ _ŒĖ@’¼’q@797
@@ 5jADAM17Œ‡Žø [”ö@•qK@800
@@ 6j–«”½•œ«‘½”­«œ‘‰ŠiCRMOjMajeedĒŒóŒQ [”ö@•qK@804
@@ 7jƒCƒ“ƒ^[ƒƒCƒLƒ“I Žó—e‘ĢhR•ŖŽqŒ‡‘¹ĒiDIRAj ’†ģ@Œ Žj@807
@@ 8jIL-36Žó—e‘ĢhR•ŖŽqŒ‡‘¹Ēi”^įv«Š£įj ™‰Y@ˆź[@811
@@ 9jHĒŒóŒQ ¬“c•x”üŽq@815
@@10jCAMPSiCARD14 mediated psoriasisj ™‰Y@ˆź[@819
@@11jƒ`ƒFƒ‹ƒrƒYƒ€ A–Ų@–õD@822
@@12j’†žŠ|¼‘ŗĒŒóŒQ ‹ąąV@L—Y@825
@@13jSAVI ˆäąV@˜aŽi@831
 9D•ā‘ĢŒ‡‘¹Ē @
@ i1ję“V«•ā‘ĢŒ‡‘¹ĒFŠT˜_ —L‰ź@@³@834
@ i2j•ā‘Ģ¬•Ŗ‚ĢŒ‡‘¹Ē @
@@ 1jC1qŒ‡‘¹Ē ’|črˆź˜Y@839
@@ 2jC1r/sŒ‡‘¹Ē ’|črˆź˜Y@843
@@ 4jC4Œ‡‘¹Ē ’|črˆź˜Y@847
@@ 5jC2Œ‡‘¹Ē ’|črˆź˜Y@851
@@ 6jC3Œ‡‘¹Ē ‘å‘q@—L‰Į@854
@@ 7jC3 gain-of-function ‘å‘q@—L‰Į@859
@@ 8jC5Œ‡‘¹Ē A–Ų@«O@863
@@ 9jC6Œ‡‘¹Ē A–Ų@«O@868
@@10jC7Œ‡‘¹Ē A–Ų@«O@870
@@11jC8Œ‡‘¹ĒiC8ƒæ-ƒĮ/ C8ƒĄŒ‡‘¹Ēj A–Ų@«O@872
@@13jC9Œ‡‘¹Ē A–Ų@«O@874
@@14jMASP-2Œ‡‘¹Ē —L‰ź@@³@877
@@15jFicolin-3Œ‡‘¹Ē‚ÉŠÖ˜A‚·‚é–ʉu•s‘S —L‰ź@@³@881
@ i3j•ā‘Ģ§ŒäˆöŽq‚ĢŒ‡‘¹Ē @
@@ 1jˆā“`«ŒŒŠĒ«•‚ŽīiC1ƒCƒ“ƒqƒrƒ^[Œ‡‘¹Ēj —L‰ź@@³@885
@@ 2jBˆöŽqŒ‡‘¹Ē ŒĖąV@—Y‰ī@889
@@ 3jDˆöŽqŒ‡‘¹Ē ŒĖąV@—Y‰ī@891
@@ 4jProperdinŒ‡‘¹Ē ŒĖąV@—Y‰ī@893
@@ 5jIˆöŽqŒ‡‘¹Ē ŒĖąV@—Y‰ī@895
@@ 6jHˆöŽqŒ‡‘¹Ē ŒĖąV@—Y‰ī@897
@@ 7jHˆöŽqŠÖ˜Aƒ^ƒ“ƒpƒNŒ‡‘¹Ē ŒĖąV@—Y‰ī@900
@@ 8jThrombomodulinˆā“`Žq‚Ģ•ĻˆŁ‚É‚ę‚é
@@@@”ń“TŒ^—nŒŒ«”A“ŏĒĒŒóŒQ6iAHUS6j
ŒĖąV@—Y‰ī@903
@@ 9j•ā‘ĢŽó—e‘Ģ2iCR2jŒ‡‘¹Ē ŒĖąV@—Y‰ī@905
@@10j•ā‘ĢŽó—e‘Ģ3iCR3jŒ‡‘¹ĒiSLE6j ŒĖąV@—Y‰ī@907
@@11jMCP iCD46jŒ‡‘¹Ē ‘å‘q@—L‰Į@909
@@12jMembrane attack complex inhibitor iCD59j Œ‡‘¹Ē ‘å‘q@—L‰Į@913
10DŒ“”­«–ʉu•s‘SĒ‚Ģ•\Œ»Œ^‚š‚Ę‚éŽ¾Š³ @
@ i1jŒć“V“I‚Čˆā“`Žq•ĻˆŁi‘Ģ×–E“Ė‘R•ĻˆŁj‚É‚ę‚鎾Š³ @
@@ 1jTNFRSF6‘Ģ×–E“Ė‘R•ĻˆŁ‚É‚ę‚é
@@@@Ž©ŒČ–ʉu«ƒŠƒ“ƒp‘BĒŒóŒQiALPS-sFASj
¼‘ŗ@@‘@917
@@ 2jKRAS‚Ģ‘Ģ×–E“Ė‘R•ĻˆŁigain-of-functionj‚É‚ę‚é
@@@@RASŠÖ˜AALPSiŽ©ŒČ–ʉu«ƒŠƒ“ƒp‘BĒj—lŽ¾Š³iRALDj
¼‘ŗ@@‘@920
@@ 3jNRAS‚Ģ‘Ģ×–E“Ė‘R•ĻˆŁigain-of-functionj‚É‚ę‚é
@@@@RASŠÖ˜AALPSiŽ©ŒČ–ʉu«ƒŠƒ“ƒp‘BĒj—lŽ¾Š³iRALDj
¼‘ŗ@@‘@924
@ i2jŒć“V“I‚ČŽ©ŒČR‘ĢŽY¶‚É‚ę‚鎾Š³ @
@@ 1jAIRE‚Ģ¶B×–E“Ė‘R•ĻˆŁAIL-17‚ą‚µ‚­‚ĶIL-22‚É‘Ī‚·‚é
@@@@Ž©ŒČR‘Ģ‚É‚ę‚閝«”ē•†”S–ŒƒJƒ“ƒWƒ_Ē
¬—с@ˆź˜Y@927
@@ 2jIFN-ƒĮ‚É‘Ī‚·‚鎩ŒČR‘Ģ‚É‚ę‚鐬l”­Ē–ʉu•s‘SĒ ‚“c@‰pr@930
@@ 3jIL-6‚É‘Ī‚·‚鎩ŒČR‘Ģ‚É‚ę‚锽•œ«”ē•†Š“õĒ ‚“c@‰pr@933
@@ 4jGM-CSF‚É‘Ī‚·‚鎩ŒČR‘Ģ‚É‚ę‚é”x–E’`”’Ē “cąV@—§”V@935
@@ 5jC1ƒCƒ“ƒqƒrƒ^[‚É‘Ī‚·‚鎩ŒČR‘Ģ‚É‚ę‚éŒć“V«ŒŒŠĒ«•‚Žī —L‰ź@@³@939
@@ 6j•ā‘ĢHˆöŽq‚É‘Ī‚·‚鎩ŒČR‘Ģ‚É‚ę‚é”ń“TŒ^—nŒŒ«”A“ŏĒĒŒóŒQ ‘å‘q@—L‰Į@942



‚²’•¶@HOME